|
Match
|
Document |
Document Title |
|
|
US20120171120 |
LOW AFFINITY BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES AND USES THEREFOR
The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same. |
|
|
US20170183414 |
Cysteine engineered antibodies for site-specific conjugation
Cysteine engineered antibodies useful for the site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such antibodies... |
|
|
US20160176974 |
METHOD FOR TREATING JOINT DAMAGE
Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject... |
|
|
US20160176966 |
ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME
A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same. |
|
|
US20160046726 |
SPECIFIC BINDING PROTEINS AND USES THEREOF
The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR... |
|
|
US20160002318 |
HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING INFLUENZA B VIRUSES AND USES THEREOF
Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses.... |
|
|
US20150368358 |
KLOTHO BETA
The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. |
|
|
US20150320880 |
ANTIBODY DRUG CONJUGATES
The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer. |
|
|
US20150307609 |
OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as... |
|
|
US20150274824 |
ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class... |
|
|
US20150232541 |
METHOD FOR MAKING ANTIBODY FC-REGION CONJUGATES COMPRISING AT LEAST ONE BINDING ENTITY THAT SPECIFICALLY BINDS TO A TARGET AND USES THEREOF
Herein is reported a method for producing an antibody Fc-region conjugate comprising as first component an antibody Fc-region and as second component at least one binding entity that specifically... |
|
|
US20150175705 |
PRLR-SPECIFIC ANTIBODY AND USES THEREOF
PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. |
|
|
US20150166659 |
Humanized L243 Antibodies
Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies,... |
|
|
US20150158952 |
CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of... |
|
|
US20150132309 |
KLOTHO BETA
The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. |
|
|
US20140377253 |
FC VARIANTS
The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors. |
|
|
US20140348784 |
COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS IN PATHOLOGICAL LESIONS
Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a... |
|
|
US20140294864 |
DRUG CONJUGATE COMPOSITION
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid.... |
|
|
US20140286968 |
ANTIBODY DRUG CONJUGATE (ADC) PURIFICATION
The invention provides methods for obtaining compositions having antibody drug conjugates (ADCs) with specified drug to antibody ratios (DARs). Included in the invention is a method for purifying... |
|
|
US20140271462 |
ANTIGEN BINDING CONSTRUCTS TO CD8
Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of... |
|
|
US20140234215 |
J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE
In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can... |
|
|
US20140199315 |
Sp35 Antibodies and Uses Thereof
Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35... |
|
|
US20140147382 |
IMMUNOTHERAPY OF B CELL MALIGNANCIES AND AUTOIMMUNE DISEASES USING UNCONJUGATED ANTIBODIES AND CONJUGATED ANTIBODIES AND ANTIBODY COMBINATIONS AND FUSION PROTEINS
The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially... |
|
|
US20130309223 |
CD33 Antibodies And Use Of Same To Treat Cancer
The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33. |
|
|
US20130243775 |
MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF
The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds... |
|
|
US20130071320 |
IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal... |
|
|
US20120276160 |
TOLEROGENIC SYNTHETIC NANOCARRIERS FOR REGULATING INNATE IMMUNE RESPONSES
Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering B cell and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to... |
|
|
US20120156218 |
NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of... |
|
|
US20120114556 |
IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal... |
|
|
US20120034185 |
ANTI-CD20 ANTIBODIES AND FUSION PROTEINS THEROF AND METHODS OF USE
The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the... |
|
|
US20120034159 |
ANTIBODIES THAT BIND BOTH BCMA AND TACI
Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic... |
|
|
US20120014952 |
COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS
Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that... |
|
|
US20120014872 |
Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Various Cancers
The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast,... |
|
|
US20110300162 |
DRUG CONJUGATE COMPOSITION
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid.... |
|
|
US20110300136 |
THERAPY OF AUTOIMMUNE DISEASE IN A PATIENT WITH AN INADEQUATE RESPONSE TO A TNF-ALPHA INHIBITOR
The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat... |
|
|
US20110268679 |
COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS
Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits... |
|
|
US20110262454 |
NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of... |
|
|
US20110243966 |
SINGLE CHAIN Fc (ScFc) REGIONS, BINDING POLYPEPTIDES COMPRISING SAME, AND METHODS RELATED THERETO
The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or... |
|
|
US20110206658 |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. |
|
|
US20110171207 |
COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND AUTO-IMMUNE DISEASES
Compositions containing soluble B7-H4 (sH4) antagonists in an amount effective to reduce, inhibit, or mitigate an inflammatory response in an individual and methods for the treatment or... |
|
|
US20110129464 |
HUMANIZED ANTI-ERBB2 ANTIBODIES AND TREATMENT WITH ANTI-ERBB2 ANTIBODIES
The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. |
|
|
US20110086050 |
GLYCOPROTEIN COMPOSITIONS
The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate... |
|
|
US20110070243 |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. |
|
|
US20110020372 |
FOLLISTATIN DOMAIN CONTAINING PROTEINS
The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly,... |
|
|
US20110008373 |
PRODRUGS OF CC-1065 ANALOGS
Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the... |
|
|
US20100297006 |
NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 191P4D12(b) USEFUL IN TREATMENT AND DETECTION OF CANCER
A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in... |
|
|
US20100291114 |
Crystal structures and methods using same
The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the... |
|
|
US20100260668 |
Dual Variable Domain Immunoglobulins and Uses Thereof
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. |
|
|
US20100255013 |
GLYCOPROTEIN COMPOSITIONS
The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate... |
|
|
US20100233121 |
METHOD FOR TREATING MULTIPLE SCLEROSIS
Methods for treating multiple sclerosis (MS) with a CD20 antibody using special dosing regimens and protocols are described. Articles of manufacture for use in such methods are also described. |